Macmillan: Review of drug information

Macmillan: Review of drug information

BOPA Members – Help required!

Macmillan produces many cancer drug treatment pages. They are widely used by healthcare professionals and people affected by cancer across the UK. We work hard to ensure that they provide the information people need to understand their treatment and ask questions. These online pages also link to other sources of information and support about cancer types, types of treatments, and managing side effects. The information needs to be current, clinically accurate and reflect the real-world patient experience.  We rely on expert speciality pharmacists to review our drug information, and make suggestions, to ensure we have met our goal.

We are always looking for specialist oncology and haematology pharmacists to join our review panel. We ask that our reviewers complete a short survey so that we can capture contact details, specialities and interests in a way that is GDPR compliant. We have a protected database to keep these details secure.

The help can range from looking at a couple of pages once or twice a year, or more if you are able. We are always flexible, you can always say “I am not able to this time” or “yes I can review, if you can give me more time”. We always appreciate that people are kindly giving us their time and expertise and we are very grateful.

We send the pages as Word documents. We ask if you could add comments and/or mark any changes using the ‘Track changes’ facility. Or you may prefer to email us with your comments.
We are generally looking for:

  • Is the information clinically accurate and up-to-date?
  • Are there any issues that you feel we have left out?
  • Is there anything that you think could have been explained more clearly?
  • Feel free to add any other comments that you have.

If you would like to join our professional reviewers or would like to find out more please contact Helen Purdon at [email protected]

Thank you for your ongoing help,
Best wishes,
Helen

Helen Purdon (She/her)
Cancer Information Development Nurse

The below pages are to be reviewed soon:

  • Stilboestrol
  • Palbociclib
  • Ribociclib
  • Doxorubicin
  • Doxorubicin and ifosfamide
  • Gefitinib
  • Midostaurin
  • De Gramont/modified de Gramont
  • Cisplatin and 5FU
  • Leuprorelin
  • CODOX-M
  • Torifemine
  • GemCarbo
  • Crizotinib
  • Rasburicase
  • EPO
  • G-CSF
  • Cabazitaxel
  • TC
  • CVP
  • Bendamustine
  • Encorafenib and binimetinib
  • Mesna

Latest News

By Education & Training Sub-Committee on 21st April 2026

NEW e-learning modules for Gastric and Oesophageal Cancers are now LIVE

The Education and Training subcommittee are pleased to announce that our new e-learning modules for Gastric and Oesophageal Cancers are now live on the BOPA website. These modules can be…

Read article
By Suriya Marshall on 21st April 2026

Join the CCLG Global Child Cancer group webinar Tackling Drug Quality in Paediatric Oncology in Low- and Middle- Income Countries (LMIC)

Calling all Paediatric Oncologists, Nurses and Pharmacists to collaborate and make a global impact Date: Thursday 14th May 2026 Time: 14:00-16:00 BST Place: Online Teams meeting Serious concerns have been…

Read article
By Farah Al-sheikhli on 16th April 2026

LCC 2026 Funding Opportunity: Pharmacist Reviewers for ‘Let’s Communicate Cancer’ Programme

Let’s Communicate Cancer review 2026 The BOPA Education and Training Subcommittee have a great opportunity for pharmacists to become involved in the review of the ‘Let’s communicate cancer’ training modules.…

Read article
By Farah Al-sheikhli on 16th April 2026

NIHR INSIGHT Opening the Doors: Reimagining Inclusion in Health Research

📅 Friday 5 June 2026  🕐 12:00–16:00  📍 1 Frith Street, London W1D 3HZ ✅ Register here About this event NIHR INSIGHT South London welcomes you to join us for an afternoon dedicated…

Read article